hotspot -WSS

hotspot

author：leisure time 2025-09-27 09:40:45 - browse：377

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Dementia risk linked to living in disadvantaged areas: Study

WSS

How to fix the rural physician shortage in the U.S.

Scientists grapple with ethics of stem cell research

Patients, doctors are clashing about side effects of hormonal birth control

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

A public health expert passes on football's full body collisions for youths

Bispecific antibodies are next new thing in cancer immunotherapy

explore

hotspot

hotspot

Heart attack and stroke risk calculators need revising

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Medicare proposal to cover medical devices draws a mixed reaction

Delta passengers in Vegas fall sick while waiting on flight in triple

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Supreme Court strikes down use of affirmative action

Hormonal contraceptives don’t actually treat endometriosis

Dobbs anniversary: the lost opportunity of abortion as health care

Millions may soon lose Medicaid when they don't have to

entertainment

Novo: Oral version of Ozempic leads to 15% weight loss

Stanford president’s abrupt resignation sparks debate

Delta passengers in Vegas fall sick while waiting on flight in triple

Hormonal contraceptives don’t actually treat endometriosis

Scientists grapple with ethics of stem cell research

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

explore

focus

entertainment

explore